RIFADIN
LOE ApproachingNDAORALCAPSULE
Approved
May 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIFADIN (rifampin) is an oral small-molecule antibiotic approved in 1971 for tuberculosis and other mycobacterial infections. It works by inhibiting bacterial RNA polymerase, disrupting pathogen transcription. The drug remains a cornerstone of TB treatment regimens globally.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); brand teams likely focused on lifecycle extension or transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RIFADIN offers limited growth-stage career opportunities due to its mature, LOE-approaching lifecycle and zero linked job openings. Roles available tend to focus on lifecycle extension, generic competition defense, and regulatory compliance rather than market expansion or innovation.
Brand ManagerProduct Manager
Worked on RIFADIN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.